Fig. 2

miR-31-5p modulation in HCC cells alters cellular sensitivity in response to Oxaliplatin-based chemotherapy treatment. a Clonogenic analysis of miR-31-5p reintroduction illustrated a significant difference between the surviving fractions of miR-VC-transfected cells treated with Oxaliplatin and the miR-31-transfected equivalent for 24 h. Furthermore, there is a significant difference between the surviving fractions of Huh7 Zip-miR-VC-transfected cells treated with Oxaliplatin and the Zip-miR-31 equivalent. b Assaying cumulative proliferation with Oxaliplatin treatment revealed a significant decrease in proliferation at all time points in miR-VC cells, whereas miR-31-5p cells appear less sensitive to the chemotherapeutic agent. The reintroduction of miR-31-5p in Hep3B cells alters cellular proliferation in response to Oxaliplatin treatment. Hep3B miR-VC cells treated with Oxaliplatin have a significant difference in proliferation compared to Hep3B miR-VC untreated cells at day 3, day 6 and day 9. There is no significant difference (ns) between the Hep-3B miR-31-5p cells treated with Oxaliplatin until day 9. Data are presented as the mean ± SEM. *p < 0.05; **p < 0.01